Weight loss and survival of BALB/c mice administered high, medium, or low doses of purified EBOV/SUDV human pAbs after maEBOV challenge.

<p>Groups of BALB/c mice (N = 10) received a single IP injection of 100mg/kg NS pAbs, 100 mg/kg EBOV/SUDV pAbs, 50 mg/kg EBOV/SUDV pAbs, or 10 mg/kg EBOV/SUDV pAbs one day after challenge or 50 mg/kg EBOV/SUDV pAbs, 25 mg/kg EBOV/SUDV pAbs, or 5 mg/kg EBOV/SUDV pAbs on day 1 and day 2 after challenge with 100 pfu maEBOV. (A) Mean weight was determined daily for each dosing group and graphed as the percent mean of the starting weight. All mice receiving the NS pabs succumb by day 8 post-challenge. (B) Kaplan-Meier survival curves indicating the percentage of surviving mice at each day of the 21-day post-challenge observation period are shown. The p-values for the following comparisons are as follows: 100 mg/kg NS pAbs vs. 100 mg/kg EBOV/SUDV pAbs +1 (<i>p</i> = 0.0003), 100 mg/kg NS pAbs vs. 50 mg/kg EBOV/SUDV pAbs +1 (<i>p</i> = 0.0059), NS pAbs vs. 10 mg/kg EBOV/SUDV pAbs +1 (<i>p</i> = 0.0630), NS pAbs vs. 50 mg/kg EBOV/SUDV pAbs +1 and +2 (<i>p</i> = 0.002), NS pAbs vs. 25 mg/kg EBOV/SUDV pAbs +1 and +2 (<i>p</i> = 0.0046), NS pAbs vs. 5mg/kg EBOV/SUDV pAbs +1 and +2 (<i>p</i> = 0.1082), 100mg/kg EBOV/SUDV pAbs +1 vs. 50 mg/kg EBOV/SUDV pAbs +1 and +2 (<i>p</i> = 0.1988), 50 mg/kg EBOV/SUDV +1 vs. 25 mg/kg EBOV/SUDV pAbs +1 and +2 (<i>p</i> = 0.9968), and 10 mg/kg EBOV/SUDV pAbs +1 vs. 5 mg/kg EBOV/SUDV pAbs +1 and +2 (<i>p</i> = 0.7275). Significant differences between survival curves are denoted by (*) where <i>p</i> < 0.05.